Identification of Human GnIH Homologs, RFRP-1 and RFRP-3, and the Cognate Receptor, GPR147 in the Human Hypothalamic Pituitary Axis

Citation for published version:
https://doi.org/10.1371/journal.pone.0008400

Digital Object Identifier (DOI):
10.1371/journal.pone.0008400

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
PLoS ONE

Publisher Rights Statement:
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Identification of Human GnIH Homologs, RFRP-1 and RFRP-3, and the Cognate Receptor, GPR147 in the Human Hypothalamic Pituitary Axis

Takayoshi Ubuka¹, Kevin Morgan², Adam J. Pawson³, Tomohiro Osugi³, Vishwajit S. Chowdhury³, Hiroyuki Minakata⁴, Kazuyoshi Tsutsu³, Robert P. Millar²,⁵, George E. Bentley¹

¹Department of Integrative Biology and Helen Wills Neuroscience Institute, University of California, Berkeley, California, United States of America, ²Medical Research Council Human Reproductive Sciences Unit, Centre for Reproductive Biology, The Queen’s Medical Research Institute, Edinburgh, United Kingdom, ³Suntory Institute for Bioorganic Research, Osaka, Japan, ⁴Department of Medical Biochemistry, University of Cape Town, Cape Town, South Africa

Abstract

The existence of a hypothalamic gonadotropin-inhibiting system has been elusive. A neuropeptide named gonadotropin-inhibitory hormone (GnIH, SIKPSAYLPLRF-NH₂) which directly inhibits gonadotropin synthesis and release from the pituitary was recently identified in quail hypothalamus. Here we identify GnIH homologs in the human hypothalamus and characterize their distribution and biological activity. GnIH homologs were isolated from the human hypothalamus by immunoaffinity purification, and then identified as MPHFSANPLRF-NH₂ (human RFRP-1) and VPNLPQRF-NH₂ (human RFRP-3) by mass spectrometry. Immunocytochemistry revealed GnIH-immunoreactive neuronal cell bodies in the dorsomedial region of the hypothalamus with axonal projections to GnRH neurons in the preoptic area as well as to the median eminence. RT-PCR and subsequent DNA sequencing of the PCR products identified human GnRH receptor (GPR147) mRNA expression in the hypothalamus as well as in the pituitary. In situ hybridization further identified the expression of GPR147 mRNA in luteinizing hormone producing cells (gonadotropes). Human RFRP-3 has recently been shown to be a potent inhibitor of gonadotropin secretion in cultured sheep pituitary cells by inhibiting Ca²⁺ mobilization. It also directly modulates GnRH neuron firing. The identification of two forms of GnIH (RFRP-1 and RFRP-3) in the human hypothalamus which targets human GnRH neurons and gonadotropes and potently inhibit gonadotropin in sheep models provides a new paradigm for the regulation of hypothalamic-pituitary-gonadal axis in man and a novel means for manipulating reproductive functions.


Editor: Immo A. Hansen, New Mexico State University, United States of America

Received July 3, 2009; Accepted November 24, 2009; Published December 22, 2009

Copyright: © 2009 Ubuka et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: Hellmann Family Foundation Fund (to G.E.B.), UC Berkeley COR Junior Faculty Research Grant (to G.E.B.), National Science Foundation (to G.E.B.), Grants-in-Aid for Scientific Research from the Ministry of Education, Science and Culture, Japan (to K.T.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

Introduction

Gonadotropin-releasing hormone (GnRH) is the primary stimulator of gonadotropin secretion [1–5]. A neuropeptide inhibitor of gonadotropin secretion has also been postulated [6–8]. The recent identification of an avian hypothalamic dodecapeptide that inhibits pituitary gonadotropin release implies that such a factor might exist in vertebrates [9]. This factor, named gonadotropin-inhibitory hormone (GnIH), is synthesized in neurons of the paraventricular nucleus (PVN) in birds [9–13]. The GnIH neurons project to the median eminence, providing neuroanatomical infrastructure to allow secretion into the hypophysial portal system and thus regulate pituitary function [9–13]. The cognate G protein-coupled receptor (GPCR) for GnIH was also identified in the quail pituitary [14] and GnIH was shown to act on the pituitary to suppress synthesis and release of gonadotropins [15]. Accordingly, GnIH inhibits the development and maintenance of gonadotropin-dependent gonadal functions [16]. Thus, while GnIH serves an important physiological role in birds [9–19], there has been limited evidence that the same is true for mammals.

GnIH homologs are present in the brains of non-human vertebrates, including mammals, amphibians and fish [20,21]. These peptides belong to the RFamide-related peptide (RFRP) [22] family and possess a characteristic C-terminal LPXRFamide (X = L or Q) motif [20,21]. The receptors for GnIH homologs have also been characterized in vertebrates [14,20–22]. Quail GnIH and rat GnIH peptide homolog, RFRP-3, inhibits luteinizing hormone (LH) secretion in Syrian hamsters [23] and rats [24,25] in vivo. It was recently shown that RFRP-3 inhibits pulsatile gonadotropin release in vivo as well as from cultured pituitary cells in sheep [26,27] and cattle [28], suggesting that a hypothalamic gonadotropin-inhibitory system also exists in mammals. Accordingly, a GnIH/RFRP system might be a conserved property of vertebrates. However, these mammalian GnIH peptide homologs were inferred from genomic sequences and the processed peptides have yet to be unequivocally identified.

* E-mail: ubukat@berkeley.edu
Here we first analyzed the existence of GnIH-immunoreactive (ir) material in human hypothalamus by immunocytochemistry (ICC). We further investigated whether there were interactions of GnIH-ir neurons with GnRH neurons by double-label ICC. We then isolated human GnIH peptide homologs (human RFRP-1 and RFRP-3) by immunoaffinity purification and identified the structure of the peptides by mass spectrometry. A G-protein coupled receptor, GPR147 (OT7T022), has been identified as the cognate receptor for RFRPs in studies investigating the role of these peptides in the central nervous system [29]. Accordingly GPR147 mRNA expression was analyzed in the hypothalamus and the pituitary by RT-PCR and DNA sequencing of the PCR products. In situ hybridization further revealed the expression of GPR147 mRNA in pituitary cells including luteinizing hormone (LH) producing cells. The human RFRP-3 was recently shown to potently inhibit GnRH stimulation of gonadotropin secretion from sheep in vivo and from cultured gonadotropes through inhibition of Ca \textsuperscript{2+} mobilization [26]. The identification of RFRP-1 and RFRP-3 and the cognate receptor GPR147 along with the demonstration of gonadotropin inhibition prompts revision of our understanding of the central control mechanism of human reproduction.

Results

Localization of GnIH-ir neurons in the human hypothalamus

ICC using avian GnIH antibody identified a group of GnIH-ir neurons in the dorsomedial region of the human hypothalamus (Fig. 1A, 1B). Some GnIH-ir fibers emanated from the infundibulum of the hypothalamus (Fig. 1A) and terminated in the external layer of the median eminence (Fig. 1C). GnIH-ir neuronal axon terminal-like structures were further observed on GnRH neurons in the preoptic area (Fig. 1D).

Identification of mature human GnIH peptide homologs

We identified the fully processed forms of GnIH homologs in the extract of human hypothalamus by using an avian GnIH antibody-conjugated immunoaffinity column and mass spectrometry. The human genome database revealed that a putative homolog of the GnIH precursor polypeptide gene is present in humans (GenBank NM_022150; 29), but the processed peptide products had not been identified until now. Because of several potential cleavage sites in the putative GnIH precursor polypeptide (Fig. 2A), there were various possible GnIH peptide products. Thus, based on the human genome, putative human RFRP-1 could be 12, 20, 24, 29, 37, 40, 44, 49 or 54 amino acids in length and human RFRP-3 could be 8 or 31 amino acids in length (Fig. 2A). Hypothalamic tissue from adult men and women was used to purify and identify human RFRP peptides by immunoaffinity purification. Two GnIH homologs were identified, the structures of which were MPHSFANLPLRF-NH\textsubscript{2} (human RFRP-1) and VPNLPQRF-NH\textsubscript{2} (human RFRP-3). The human genome database also predicted the presence of an RFRP-like peptide which has a C-terminus LPLRSamide motif, but this was not detected, possibly because of the difference in the C-terminal amino acid compared to avian GnIH, or because this peptide is not processed from the precursor. The precise mechanism of how the GnIH/RFRP precursor protein is processed into mature peptides and how this process differs between species is unknown. GnIH-ir neurons were observed in the dorsomedial region of the human hypothalamus. The location of GnIH neuronal cell bodies were in general agreement to hamsters (dorsomedial hypothalamus; 23) and sheep (dorsomedial hypothalamic nucleus and paraventricular nucleus; 26). GnIH-ir axon terminal like structures were observed in close proximity to GnRH neurons in the preoptic area suggesting the regulation of GnRH neurons by GnIH. The interaction of GnIH-ir fibers with GnRH neurons is consistent with results in birds [17,19], rodents [23] sheep [31] and monkey [32]. In starlings, GnIH receptor (GPR147) mRNA is expressed in GnRH neurons [19] and we demonstrated expression of the GPR147 in human hypothalamus. The possibility that GnIH affects GnRH neuron activity is supported by the recent demonstration that RFRP administration reduces the firing activity [33,34] and immediate early gene expression in GnRH neurons [35]. GnIH-ir axons also projected to the neurosecretory zone of the median eminence suggesting that GnIH might also directly regulate pituitary function. The expression of the human GPR147 mRNA in the pituitary supports this notion. Moreover, in situ hybridization for GPR147 mRNA in conjunction with...
immunocytochemistry for human LH further showed the expression of GPR147 mRNA in gonadotropes of the adult human anterior pituitary. Accordingly, human GnIH homologs may regulate gonadotropin secretion by inhibiting GnRH neurons as well as directly acting on gonadotrope cells in the pituitary as was clearly demonstrated in isolated pituitary cells in the sheep [26,27].

Our identification of RFRP-1 and RFRP-3 peptides in the human hypothalamus and the ICC demonstration of targeting GnRH neurons in the human hypothalamus along with the expression of GPR147 in human gonadotropes provide a cogent framework for RFRP regulation of human reproduction. The question arises as to whether the human RPRP peptides are biologically active and inhibit gonadotropins. Similarly, we studied the effects of human RFRP on the mouse gonadotrope LβT2 cell line but detected no effects on any signaling pathway. When we checked GPR147 expression by RT-PCR no products were detected in this immature gonadotrope cell line (data not shown). We detected inhibitory effects in human fetal pituitary cells, but these were inconsistent even though they exhibited robust gonadotropin responses to GnRH (data not shown). This variability may be due to the immaturity of the gonadotropes.

**Figure 1. GnIH immunoreactive neurons in the human hypothalamus and GnIH receptor mRNA in the human pituitary.** (A) Coronal section of adult human hypothalamus showing GnIH immunoreactive (ir) neurons clustered in the dorsomedial region of the hypothalamus with their fibers extending to the infundibulum (INF). III, third ventricle. Bar, 1 mm. (B) Higher magnification of GnIH-ir neuronal cell bodies. Bar, 50 μm. (C) Sagittal section of the median eminence showing dense population of GnIH-ir fibers within the external layer. Bar, 10 μm. (D) GnIH-ir axon terminal like structures (stained in purple, indicated by black arrows) in close proximity to a GnRH-ir neuronal cell body (stained in brown) in the preoptic area. Bar, 50 μm. (E and F) In situ hybridization of human GnIH receptor (GPR147) mRNA in the human anterior pituitary (E) in combination with immunocytochemistry for luteinizing hormone (LH) (F). Red arrows in (E) and white arrows in (F) in equivalent positions show cells which express both GPR147 mRNA and LH. Bars, 30 μm. (G and H) In situ hybridization using sense RNA probe (G) and immunocytochemistry without LH primary antiserum (H) served as controls. Bars, 30 μm.

doi:10.1371/journal.pone.0008400.g001
However, human RFRP-3, which is identical in sequence to sheep RFRP-3, potently inhibits gonadotropin secretion in vivo in sheep and GnRH stimulation of gonadotropin secretion from cultured sheep pituitary cells [26,27]. This strongly suggests RFRP-3 would also be active in the direct inhibition of gonadotropin release from gonadotropes in man. The demonstration that RFRP regulates GnRH neuron firing and early gene expression [33–35] suggests that the peptides may also be effective at this level in man. The question also arises as to whether RFRP-1 and RFRP-3 have similar or different functions. It appears from the large pain literature that they both bind GPR147 with similar affinity and recruit similar signalling pathways. Thus, the presence of two peptide products from the same gene may be a means for signal amplification.

The identification of novel RFamide-related peptides (RFRP-1 and RFRP-3) in the human hypothalamus and the demonstration that human RFRP-3 has potent inhibitory actions on gonadotropin secretion in animal models opens up new vistas for understanding the regulation of reproduction. Many factors such as stress, anorexia, diabetes, obesity and photoperiod inhibit gonadotropin secretion. The possible role of GnIH in mediating these effects has been implicated in animal models [30,36,37]. GnRH analogues are extensively employed to manipulate the hypothalamic-pituitary-gonadal axis in various clinical conditions [38–40]. In view of its potent inhibition of gonadotropes, GnIH has the potential of an alternative or adjunct therapeutic agent to inhibit gonadotropins and steroid hormones. Thus this endogenous inhibitor of gonadotropin secretion has therapeutic potential in the treatment of hormone-dependent diseases such as precocious puberty, endometriosis, uterine fibroids, benign prostatic hyperplasia and prostatic and breast cancers. Human GnIH may also have potential as a novel contraceptive.

Table 1. Behavior of Native and Synthetic Human RFRP-1 and RFRP-3 on MALDI-TOF MS.

<table>
<thead>
<tr>
<th></th>
<th>Observed Mass m/z ([M-H]+)</th>
<th>Observed Mass m/z ([M-H]+)</th>
<th>Theoretical Mass m/z ([M-H]+)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Native</td>
<td>Synthetic</td>
<td></td>
</tr>
<tr>
<td>Human RFRP-1</td>
<td>1428.85</td>
<td>1428.91</td>
<td>1428.75</td>
</tr>
<tr>
<td>Human RFRP-3</td>
<td>969.48</td>
<td>969.81</td>
<td>969.56</td>
</tr>
</tbody>
</table>

do:10.1371/journal.pone.0008400.t001
Materials and Methods

Human hypothalamus and pituitary tissue

Frozen and fixed adult human hypothalamus and pituitary tissue were obtained from Harvard Brain Tissue Resource Center (Belmont, MA). All donations were with fully informed consent by written statements from the deceased individuals. The research was approved by the ethics committee of the Harvard Brain Tissue Resource Center, McLean Hospital (Belmont, MA) (Director: Francine M. Benes, M.D., Ph.D.) and the IRB. All procedures were performed in accordance with the NIH Guide and under an approved protocol from the University of California.

Immunocytochemistry of human GnIH peptide

Immunocytochemical analysis of GnIH was conducted with slight modifications of our previous method [19] on coronal sections at 40 μm thickness of five fixed human hypothalami. Sections were first post-fixed in 4% PFA for 30 min, and incubated in 0.3% H₂O₂ in absolute methanol for 20 min to suppress endogenous peroxidase activity after washing the sections three times in phosphate-buffered saline (PBS; 10 mM phosphate buffer, 0.14 M NaCl, pH 7.4). Sections were washed three times in PBS and incubated overnight at 4 °C in the primary antibody at a concentration of 1:5,000 in PBS-T (0.2% Triton X-100 in PBS). The primary antibody used was affinity column purified rabbit anti-white-crowned sparrow GnIH peptide (code: PAC 123/124, G.E.B.). The next day, three subsequent washes in PBS were followed by incubation in biotinylated goat anti-rabbit IgG (1:250 in PBS-T) for 1 h. After washing the sections in PBS-T three times, they were incubated for 1 h in avidin-biotin complex (ABC; Vectastain Elite Kit, Vector Laboratories, Burlingame, CA) in PBS-T. The resulting complex was visualized using Vector VIP (Vector Laboratories). Thus GnIH fibers were labeled in purple by Vector VIP, whereas GnRH fibers were labeled in brown by DAB.

Immunofinity purification and mass spectrometry of human GnIH peptide

To identify the structure of the mature human GnIH peptide, we first collected GnIH-Ir material from brain extract as follows, using an antiserum raised against quail GnIH [9]. Five frozen human hypothalami (total weight 5.8 g) were boiled and homogenized in 5% acetic acid, as described previously [42]. The homogenate was centrifuged at 10,000 g for 30 min at 4 °C, and the supernatant was collected. The collected supernatant was passed through a disposable C-18 cartridge column (Mega Bond-Elut; Varian, Harbor, CA, USA). The retained material eluted with 60% methanol was concentrated by using an evaporator and loaded onto an immunofinity column. The affinity chromatography was carried out as previously described [43]. The antiserum against quail GnIH was conjugated to cyanogen bromide-activated Sepharose 4B (Amersham Pharmacia Biotech, Uppsala, Sweden) as an affinity ligand. The concentrated material was applied to the immunofinity column at 4 °C and the adsorbed materials were eluted with 0.3 M acetic acid containing 0.1% 2-mercaptoethanol. The eluted fractions were again concentrated and subjected to a reversed-phase HPLC column (ODS-80TM; Tosoh, Tokyo, Japan) with a linear gradient of 10–50% acetonitrile containing 0.1% trifluoroacetic acid at a flow rate of 0.5 ml/min, and fractionated every 2 min for 100 min. The immunoreactive fraction was assayed by a dot immunoblot assay and the molecular mass of the material was analyzed by matrix-assisted laser desorption/ionization-time-of-flight-mass spectrometry (MALDI-TOF MS; AXIMA-CFRplus, Shimadzu, Kyoto, Japan). MPHFSANPLLRF-NH₂ (human RFRP-1) and VPPLPQRF-NH₂ (human RFRP-3) were predicted.
as the mature peptides from the deduced amino acid sequence of the human genome sequence. Accordingly, the peptide was synthesized by using a peptide synthesizer (PSSM-8; Shimadzu) and the molecular behavior of the synthetic and native peptides was compared by MALDI-TOF MS. Furthermore, fragmentation of the synthetic and native peptides were analyzed by tandem MS.

**RT-PCR and DNA sequencing of human RFRP receptor cDNA**

One human hypothalamic and one human pituitary were used for the identification of a cDNA encoding human GPR147. Total RNA (including rRNA and mRNA) was isolated by using TRIZOL (Invitrogen, Carlsbad, CA). Total RNA was reverse transcribed using oligo(deoxynucleotidyl):15 primer (Promega, Madison, WI) and reverse transcriptase (M-MLV Reverse Transcriptase; Invitrogen). Partial human GPR147 cDNA was amplified by PCR using various primers based on human GPR147 cDNA sequence (NM_022146). Combinations of forward primer 1 (F1: 5'-ATGTTCTACCTCAACCTGGCTGTC-3'), forward primer 2 (F2: 5'-TTTGTGGACAACTCTACATCTGGGTG-3'), forward primer 3 (F3: 5'-TTTTCACACTGGTGCCATTGCTG-3') against a reverse primer (R1: 5'-ATGGGCGGCTGATCATGACCGATGAA-3') produced PCR products. All PCR amplifications were performed in a reaction mixture containing Taq polymerase (TaKaRa Ex TaqTM; Takara Bio Inc., Shiga, Japan). PCR products were sub-cloned into a pGEM-T Easy vector (Promega) and the DNA inserts of the positive clones were amplified by PCR with universal M13 primers. Amplified DNA was sequenced at the UC Berkeley DNA sequencing facility (Berkeley, CA) using 3730xl DNA Analyzer (Applied Biosystems, Foster City, CA).

**In situ hybridization for human GnIH receptor, GPR147, mRNA and double staining with LH ICC**

Coronal sections at 40 μm thickness of four frozen human pituitaries were collected on a cryostat at ~20°C for histological studies. In situ hybridization was carried out with slight modifications of our previous method [36] using a digoxigenin (DIG)-labeled antisense RNA probe. The DIG-labeled antisense RNA probe was produced using a standard RNA labeling kit (Roche Diagnostics) by using partial GPR147 cDNA (nt 302–716 in NM_022146) as a template. Defrosted sections were first fixed in 4% paraformaldehyde (PFA) for 30 min. After washing the sections three times in PBS, they were incubated for 10 min with 0.2 N HCl at 37°C for 30 min. Sections were fixed again for 10 min in 4% PFA, and then treated with 0.2 N HCl for 10 min after rinsing the sections in PBS. The sections were rinsed three times in PBS, they were incubated in 1.5% DIG blocking reagent in PBS and once in alkaline phosphate buffer (pH 9.5), the sections were incubated with goat anti-rabbit antibody (Roche Diagnostics) in 1.5% DIG blocking reagent and reverse transcriptase (M-MLV Reverse Transcriptase; Invitrogen). Partial human GPR147 cDNA was amplified by PCR using various primers based on human GPR147 cDNA sequence (NM_022146). Combinations of forward primer 1 (F1: 5'-ATGTTCTACCTCAACCTGGCTGTC-3'), forward primer 2 (F2: 5'-TTTGTGGACAACTCTACATCTGGGTG-3'), forward primer 3 (F3: 5'-TTTTCACACTGGTGCCATTGCTG-3') against a reverse primer (R1: 5'-ATGGGCGGCTGATCATGACCGATGAA-3') produced PCR products. All PCR amplifications were performed in a reaction mixture containing Taq polymerase (TaKaRa Ex TaqTM; Takara Bio Inc., Shiga, Japan). PCR products were sub-cloned into a pGEM-T Easy vector (Promega) and the DNA inserts of the positive clones were amplified by PCR with universal M13 primers. Amplified DNA was sequenced at the UC Berkeley DNA sequencing facility (Berkeley, CA) using 3730xl DNA Analyzer (Applied Biosystems, Foster City, CA).

**References**


